Przejdź do treści

Filtry

Dane naukowe

Podręcznik/instrukcje

Aktualności

Betamimetics for suspected impaired fetal growth

Too little evidence to show whether betamimetic drugs for women during pregnancy benefits unborn babies who are smaller than expected.

Betamimetic drugs such as ritodrine relax muscles and help the body break down sugar found in fruit and meat (glucose) for energy. It has been thought that betamimetic drugs taken by mouth or injection by women who are more than 27 weeks' pregnant may improve the growth of unborn babies who are smaller than expected (impaired fetal growth). The review of two trials (118 women) has found too little evidence to show whether the unborn baby's growth improves when the mother takes betamimetic drugs. More research is needed into the short and long-term effects of betamimetic drugs on women and their babies.

Wprowadzenie

Betamimetic drugs may promote fetal growth by increasing the availability of nutrients and by decreasing vascular resistance. They may also induce adverse effects via their effects on carbohydrate metabolism.

Cele

The objective of this review was to assess the effects of betamimetic therapy for suspected impaired fetal growth on fetal growth and perinatal outcome.

Metody wyszukiwania badań

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2009).

Kryteria doboru badań

Randomized trials of betamimetic therapy compared with no betamimetic therapy or placebo in women with suspected impaired fetal growth.

Zbieranie i analiza danych

Eligibility and trial quality was assessed.

Główne wyniki

Two studies of 118 women were included. No statistically significant differences were found between the betamimetic groups and the control groups for low birthweight (risk ratio 1.17, 95% confidence interval 0.75 to 1.83), other anthropometric measures or neonatal morbidity and mortality.

Wnioski autorów

Larger, well-designed studies are needed to evaluate the effects of betamimetics on fetal growth. Since there is potential for adverse effects due to the pharmacological characteristics of this group of drugs, data related to any potential harms should be collected in addition to beneficial effects.

Cytowanie
Say L, Gülmezoglu AM, Hofmeyr GJ. Betamimetics for suspected impaired fetal growth. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD000036. DOI: 10.1002/14651858.CD000036.

Używamy plików cookie

Używamy niezbędnych plików cookie, aby nasza strona mogła działać. Chcielibyśmy również ustawić opcjonalne pliki cookie do analizy, aby pomóc nam udoskonalić tę stronę. Nie będziemy ustawiać opcjonalnych plików cookie, chyba że je włączysz. Użycie tego narzędzia spowoduje ustawienie pliku cookie na Twoim urządzeniu, aby zapamiętać Twoje preferencje. W każdej chwili możesz zmienić swoje preferencje dotyczące plików cookie, klikając na link "Ustawienia plików cookie" znajdujący się w stopce każdej strony.
Bardziej szczegółowe informacje na temat używanych przez nas plików cookie można znaleźć na naszej stronieStrona plików cookies

Zaakceptuj wszystkie
Skonfiguruj